Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Dermatology

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 101 articles:
HTML format



Single Articles


    March 2024
  1. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    PubMed     Abstract available


  2. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed     Abstract available


    February 2024
  3. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    PubMed     Abstract available


  4. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    PubMed     Abstract available


  5. KIMBALL AB, Ravichandran S
    Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
    Lancet. 2024;403:617-618.
    PubMed    


  6. ENDO M, Kami M
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:617.
    PubMed    


  7. MAUL JT, Kolios AGA, Thomsen SF, Ring HC, et al
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:616-617.
    PubMed    


    January 2024
  8. BAKKER T, Klopotowska JE, Dongelmans DA, Eslami S, et al
    The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial.
    Lancet. 2024 Jan 19:S0140-6736(23)02465-0. doi: 10.1016/S0140-6736(23)02465.
    PubMed     Abstract available


  9. WEBER JS, Carlino MS, Khattak A, Meniawy T, et al
    Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
    Lancet. 2024 Jan 18:S0140-6736(23)02268-7. doi: 10.1016/S0140-6736(23)02268.
    PubMed     Abstract available


  10. MAURER M, Ensina LF, Gimenez-Arnau AM, Sussman G, et al
    Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Lancet. 2024;403:147-159.
    PubMed     Abstract available


  11. MOUSSA S, Netchiporouk E
    Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
    Lancet. 2024;403:118-119.
    PubMed    


    December 2023
  12. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available


  13. BRAUNSTEIN LZ
    Optimising adjuvant breast radiotherapy via preoperative imaging.
    Lancet. 2023 Dec 5:S0140-6736(23)02698-3. doi: 10.1016/S0140-6736(23)02698.
    PubMed    


  14. MANN GB, Skandarajah AR, Zdenkowski N, Hughes J, et al
    Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
    Lancet. 2023 Dec 5:S0140-6736(23)02476-5. doi: 10.1016/S0140-6736(23)02476.
    PubMed     Abstract available


    November 2023
  15. SAKAI K, Miyamori D
    Hyperviscosity syndrome caused by cryoglobulinemia diagnosed by observing the reversible formation of gel upon cooling and warming the patient's serum.
    Lancet. 2023;402:1866.
    PubMed    


  16. DEVJANI S, Engel PV, Javadi SS, Smith B, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.
    Lancet. 2023;402:1833-1834.
    PubMed    


  17. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
    Lancet. 2023;402:1834.
    PubMed    



  18. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
    Lancet. 2023 Nov 3:S0140-6736(23)01082-6. doi: 10.1016/S0140-6736(23)01082.
    PubMed     Abstract available


  19. LEVINE MN
    Effective and safe regional node irradiation in early breast cancer.
    Lancet. 2023 Nov 3:S0140-6736(23)01614-8. doi: 10.1016/S0140-6736(23)01614.
    PubMed    


  20. ZAMAN M, de Vale ML, Coultas C, Goff L, et al
    Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.
    Lancet. 2023;402 Suppl 1:S96.
    PubMed     Abstract available


  21. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available


  22. HUNTLEY C, Torr B, Sud A, Houlston RS, et al
    The impact of risk stratification by polygenic risk and age on breast cancer screening in women aged 40-49 years: a modelling study.
    Lancet. 2023;402 Suppl 1:S54.
    PubMed     Abstract available


  23. ACHARYA A, Darzi A, Judah G
    An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S17.
    PubMed     Abstract available


    October 2023
  24. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    PubMed     Abstract available


    September 2023
  25. HANOUNEH M, Arend LJ
    Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease.
    Lancet. 2023;402:1083-1084.
    PubMed    


  26. JO SJ, Jaihyun Cho R
    Preventing generalised pustular psoriasis.
    Lancet. 2023 Sep 19:S0140-6736(23)01480-0. doi: 10.1016/S0140-6736(23)01480.
    PubMed    


  27. MORITA A, Strober B, Burden AD, Choon SE, et al
    Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Lancet. 2023 Sep 19:S0140-6736(23)01378-8. doi: 10.1016/S0140-6736(23)01378.
    PubMed     Abstract available


  28. BECKER JC, Ugurel S, Leiter U, Meier F, et al
    Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
    Lancet. 2023;402:798-808.
    PubMed     Abstract available


  29. SAIAG P, Blom A
    Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
    Lancet. 2023;402:751-753.
    PubMed    


  30. MANSFIELD BS, Raal FJ
    Regression of cutaneous xanthomata in patient with homozygous familial hypercholesterolemia using novel therapies.
    Lancet. 2023;402:e11.
    PubMed    


    August 2023
  31. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Aug 23:S0140-6736(23)01245-X. doi: 10.1016/S0140-6736(23)01245.
    PubMed     Abstract available


  32. THORNTON J
    Scabies in Cox's Bazar.
    Lancet. 2023;402:600.
    PubMed    


    July 2023
  33. LONG GV, Swetter SM, Menzies AM, Gershenwald JE, et al
    Cutaneous melanoma.
    Lancet. 2023 Jul 24:S0140-6736(23)00821-8. doi: 10.1016/S0140-6736(23)00821.
    PubMed     Abstract available


    June 2023
  34. COLES CE, Haviland JS, Kirby AM, Griffin CL, et al
    Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
    Lancet. 2023 Jun 8:S0140-6736(23)00619-0. doi: 10.1016/S0140-6736(23)00619.
    PubMed     Abstract available


    April 2023
  35. IQBAL M, Kharfan-Dabaja MA
    Cogent data on allogeneic haematopoietic stem-cell transplantation efficacy in advanced cutaneous T-cell lymphoma.
    Lancet. 2023 Apr 24:S0140-6736(23)00631-1. doi: 10.1016/S0140-6736(23)00631.
    PubMed    


  36. DE MASSON A, Beylot-Barry M, Ram-Wolff C, Mear JB, et al
    Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
    Lancet. 2023 Apr 24:S0140-6736(23)00329-X. doi: 10.1016/S0140-6736(23)00329.
    PubMed     Abstract available


  37. HAKIMI M, North JP, Taylor MA, Hailer A, et al
    Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease.
    Lancet. 2023;401:1381.
    PubMed    


  38. ANDRE F, Hee Park Y, Kim SB, Takano T, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Apr 19:S0140-6736(23)00725-0. doi: 10.1016/S0140-6736(23)00725.
    PubMed     Abstract available


  39. CHUMSRI S
    Advancing outcomes of metastatic HER2-positive breast cancer.
    Lancet. 2023 Apr 19:S0140-6736(23)00805-X. doi: 10.1016/S0140-6736(23)00805.
    PubMed    



  40. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    Lancet. 2023;401:1277-1292.
    PubMed     Abstract available


  41. SHEN SJ, Liu CM
    Chemotherapy for early-stage breast cancer: the more the better?
    Lancet. 2023;401:1243-1245.
    PubMed    


  42. MULLER M, Ingold-Heppner B, Stocker H, Heppner FL, et al
    Skin lesion specimens as first choice to detect monkeypox virus - Authors' reply.
    Lancet. 2023;401:1265.
    PubMed    


  43. ZHOU YB
    Skin lesion specimens as first choice to detect monkeypox virus.
    Lancet. 2023;401:1264-1265.
    PubMed    


  44. KING B, Zhang X, Harcha WG, Szepietowski JC, et al
    Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
    Lancet. 2023 Apr 13:S0140-6736(23)00222-2. doi: 10.1016/S0140-6736(23)00222.
    PubMed     Abstract available


  45. JAVAUD N, Gobert D
    Hereditary angioedema: is there a better future for treatment?
    Lancet. 2023;401:1054-1055.
    PubMed    


  46. CRAIG TJ, Reshef A, Li HH, Jacobs JS, et al
    Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023;401:1079-1090.
    PubMed     Abstract available


    March 2023
  47. EGEBERG A, Thyssen JP
    The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.
    Lancet. 2023;401:708-710.
    PubMed    


  48. KIMBALL AB, Jemec GBE, Alavi A, Reguiai Z, et al
    Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Lancet. 2023;401:747-761.
    PubMed     Abstract available


    February 2023
  49. CORREA-SELM L, Hanlon KL, Grichnik JM
    Differentiating activated Langerhans cells and dendritic melanocytes using reflectance confocal microscopy: the limitations of diagnosing melanoma in vivo.
    Lancet. 2023;401:590.
    PubMed    


  50. AYGOREN-PURSUN E, Zanichelli A, Cohn DM, Cancian M, et al
    An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Lancet. 2023;401:458-469.
    PubMed     Abstract available


  51. RESHEF A, Grumach AS
    New medications to mitigate attacks of hereditary angioedema: does one size fit all?
    Lancet. 2023;401:413-415.
    PubMed    


    January 2023
  52. VOLKMANN ER, Andreasson K, Smith V
    Systemic sclerosis.
    Lancet. 2023;401:304-318.
    PubMed     Abstract available


  53. ZHOU YB
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed.
    Lancet. 2023;401:104.
    PubMed    


  54. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed - Authors' reply.
    Lancet. 2023;401:104.
    PubMed    


  55. CHUA BH, Link EK, Kunkler IH, Olivotto IA, et al
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
    Lancet. 2023;401:24.
    PubMed    


  56. MULLIEZ T, De Ridder M
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
    Lancet. 2023;401:23-24.
    PubMed    


  57. MEROLA JF, Landewe R, McInnes IB, Mease PJ, et al
    Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Lancet. 2023;401:38-48.
    PubMed     Abstract available


  58. QUEIRO R
    Bimekizumab in psoriatic arthritis: a great leap forward?
    Lancet. 2023;401:2-3.
    PubMed    


  59. MCINNES IB, Asahina A, Coates LC, Landewe R, et al
    Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    Lancet. 2023;401:25-37.
    PubMed     Abstract available


  60. MITJA O, Ogoina D, Titanji BK, Galvan C, et al
    Monkeypox.
    Lancet. 2023;401:60-74.
    PubMed     Abstract available


    December 2022
  61. THYSSEN JP, Schmid-Grendelmeier P
    Long-term disease control in atopic dermatitis using biologics.
    Lancet. 2022 Dec 9:S0140-6736(22)02347-9. doi: 10.1016/S0140-6736(22)02347.
    PubMed    


  62. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Lancet. 2022 Dec 9:S0140-6736(22)02037-2. doi: 10.1016/S0140-6736(22)02037.
    PubMed     Abstract available


  63. RASSY E, Delaloge S
    A second-generation antibody-drug conjugate to treat HER2-positive breast cancer.
    Lancet. 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.
    PubMed    


  64. HURVITZ SA, Hegg R, Chung WP, Im SA, et al
    Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420.
    PubMed     Abstract available


    November 2022
  65. SANCHEZ-MEZA E, Kubelis-Lopez DE, Ocampo-Candiani J, Chavez-Alvarez S, et al
    Prominent skin folds of the scalp provide a superficial clue in acromegaly.
    Lancet. 2022;400:1802.
    PubMed    


  66. VRSELJA A, Latifi A, Baber RJ, Stuckey BGA, et al
    Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1704-1711.
    PubMed     Abstract available


  67. CRANDALL CJ, Ganz PA
    Phase 2 data on a new treatment for hot flushes in women with breast cancer.
    Lancet. 2022;400:1659-1661.
    PubMed    


    October 2022

  68. Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial.
    Lancet. 2022;400:1334-1344.
    PubMed     Abstract available


    September 2022
  69. KIM S, Wuthrick E, Blakaj D, Eroglu Z, et al
    Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Lancet. 2022;400:1008-1019.
    PubMed     Abstract available


  70. SAIAG P, Blom A
    Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma.
    Lancet. 2022;400:976-977.
    PubMed    


  71. PALLER AS, Simpson EL, Siegfried EC, Cork MJ, et al
    Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2022;400:908-919.
    PubMed     Abstract available


  72. HALLING AS, Thyssen JP
    Biological therapy for young children with atopic dermatitis.
    Lancet. 2022;400:867-869.
    PubMed    


  73. LIVINGSTONE E, Zimmer L, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01654.
    PubMed     Abstract available


  74. SMITHY JW, Postow MA
    Adjuvant checkpoint blockade following complete local therapy for melanoma metastases.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01748.
    PubMed    


    August 2022
  75. DESCAMPS V
    DRESS syndrome.
    Lancet. 2022;400:560.
    PubMed    


  76. HINDIE E
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed?
    Lancet. 2022;400:559.
    PubMed    


  77. LUKE JJ, Ibrahim N, Eggermont AM
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply.
    Lancet. 2022;400:559-560.
    PubMed    


  78. CHUA BH, Link EK, Kunkler IH, Whelan TJ, et al
    Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
    Lancet. 2022;400:431-440.
    PubMed     Abstract available


  79. COLES CE, Chatterjee S, Jagsi R, Kirby AM, et al
    Breast radiotherapy for ductal carcinoma in situ: could less be more?
    Lancet. 2022;400:408-410.
    PubMed    


    July 2022
  80. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    PubMed     Abstract available


  81. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.
    PubMed    


  82. RUDD EC, Kulasekararaj A, Basu TN
    Facial lymphoedema, viral warts, and myelodysplastic syndrome: the protean condition of GATA2 deficiency.
    Lancet. 2022;400:236.
    PubMed    


    June 2022
  83. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    PubMed     Abstract available


  84. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Sweet's syndrome and Crohn's disease diagnosed simultaneously.
    Lancet. 2022;399:2155.
    PubMed    


    May 2022
  85. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.
    PubMed    


  86. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    PubMed     Abstract available


  87. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.
    PubMed    


    April 2022
  88. MEGALY M, Boshra N
    Pyogenic granuloma-like Kaposi's sarcoma.
    Lancet. 2022;399:e38.
    PubMed    


  89. TCHERNEV G, Chokoeva AA
    Melanoma in a Chinese dragon tattoo.
    Lancet. 2022;399:e37.
    PubMed    


    March 2022
  90. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
    PubMed     Abstract available


  91. DRIVENES JL, Betz RC, Bygum A
    A girl with unruly locks: molecular genetics makes a diagnosis of uncombable hair syndrome.
    Lancet. 2022;399:1079.
    PubMed    


  92. CRAIG T, Magerl M, Levy DS, Reshef A, et al
    Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2022;399:945-955.
    PubMed     Abstract available


  93. FIJEN LM, Levi M
    Prophylaxis with anti-activated factor XII for hereditary angioedema.
    Lancet. 2022;399:889-890.
    PubMed    


    February 2022
  94. KUMAR A, Preston N, Phillips R
    Picturing health: Buruli ulcer in Ghana.
    Lancet. 2022;399:786-797.
    PubMed    


  95. COLES CE, Anderson BO, Cameron D, Cardoso F, et al
    The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00184.
    PubMed    


    December 2021
  96. AL-MATAR SH, Sairam C, Roussel L, Langelier MJ, et al
    Fever, abdominal pain, serositis, arthralgia, hearing loss, proteinuria, and a family history: Muckle Wells syndrome.
    Lancet. 2021;398:2101.
    PubMed    


    November 2021
  97. MURPHY MJ, Damsky W, Vesely MD
    A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenon.
    Lancet. 2021;398:1836.
    PubMed    


    October 2021
  98. GONZALES E, Hardikar W, Stormon M, Baker A, et al
    Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Lancet. 2021;398:1581-1592.
    PubMed     Abstract available


    April 2021
  99. LOIBL S, Poortmans P, Morrow M, Denkert C, et al
    Breast cancer.
    Lancet. 2021 Apr 1. pii: S0140-6736(20)32381.
    PubMed     Abstract available


    March 2021
  100. WANG C, Li A, Shi Q, Yu Z, et al
    Metagenomic next-generation sequencing clinches diagnosis of leishmaniasis.
    Lancet. 2021;397:1213.
    PubMed    


    January 2021

  101. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
    Lancet. 2021;397:387-397.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.